REG - Polarean Imaging PLC - Notice of Results

Polarean ImagingAnnouncement

21/08/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240821:nRSU1391Ba&default-theme=true

RNS Number : 1391B  Polarean Imaging PLC  21 August 2024

Polarean Imaging plc

("Polarean" or the "Company")

 

Notice of results

 

Polarean Imaging plc (AIM: POLX), a commercial-stage medical device leader in
advanced Magnetic Resonance Imaging ("MRI") of lung function, confirms that it
will be announcing its half year results for the six months ended 30 June 2024
on Wednesday, 4 September 2024.

 

Christopher von Jako, Ph.D., Chief Executive Officer, and Charles Osborne,
Chief Financial Officer, will be hosting a live online presentation relating
to the results via the Investor Meet Company platform on Wednesday, 4
September 2024 at 17.30 BST.

 

The presentation is open to all existing and potential shareholders. Questions
can be submitted pre-event via your IMC dashboard up until 09:00 BST the day
before the meeting or in real time during the presentation.

 

Investors can sign up to Investor Meet Company for free and add to meet
Polarean Imaging plc here
(https://www.investormeetcompany.com/polarean-imaging-plc/register-investor) .
Investors who already follow Polarean on the Investor Meet Company platform
will automatically be invited.

 

Whilst the Company may not be in a position to answer every question it
receives, it will address the most prominent within the confines of
information already disclosed to the market through regulatory notifications.
A recording of the presentation will be available on the Investor Meet Company
platform afterwards.

 

Enquiries:

 

 Polarean Imaging plc             www.polarean.com / www.polarean-ir.com
 Christopher von Jako, Ph.D., Chief Executive Officer           Via Walbrook PR

 Charles Osborne, Chief Financial Officer

 Stifel (NOMAD and Sole Corporate Broker)                                       +44 (0)20 7710 7600
 Nicholas Moore / Nick Harland / Ben Good

 Walbrook PR                      Tel: +44 (0)20 7933 8780 or polarean@walbrookpr.com
 Anna Dunphy / Phillip Marriage   Mob: +44 (0)7876 741 001 / +44 (0)7867 984 082

 

About Polarean

Polarean is a revenue-generating medical imaging technology company
revolutionising pulmonary medicine through direct visualisation of lung
function by introducing the power and safety of MRI to the respiratory
healthcare community. This community is in desperate need of modern solutions
to accurately assess lung function. The Company strives to optimise lung
health and prevent avoidable loss by illuminating hidden disease, addressing
the global unmet medical needs of more than 500 million patients worldwide
suffering from chronic respiratory disease. Polarean is a leader in the field
of hyperpolarisation science and has successfully developed the first and only
hyperpolarised Xenon MRI inhaled contrast agent, XENOVIEW™, which is now
FDA-approved in the United States. Polarean is dedicated to researching,
developing, and commercialising innovative imaging solutions with its
non-invasive and radiation-free pulmonary functional MRI platform. This
comprehensive drug-device platform encompasses the proprietary Xenon gas
blend, gas hyperpolarisation system, as well as software and accessories,
facilitating fully integrated modern respiratory imaging operations. Founded
in 2012, with offices in Durham, NC, and London, United Kingdom, Polarean is
committed to increasing global awareness of and broad access to its XENOVIEW
MRI technology platform. For the latest news and information about Polarean,
please visit www.polarean.com (http://www.polarean.com/) .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NORGZGZRFGZGDZM